Shares of DURECT Co. (NASDAQ:DRRX – Get Free Report) have received a consensus rating of “Moderate Buy” from the five research firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target […]

Related Keywords

, Investors Inc , Cm Management , Ironwood Investment Management , Richmond Brothers Inc , Nasdaq , Company Profile , Get Free Report , Investment Management , Accredited Investors , Get Free , Durect , Nasdaq Drrx , Drrx , Medical , Ratings , Consensus ,